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Expression of sperm protein 17 (Sp17) mRNA has been reported in various malignancies. In an earlier study, we reported the
upregulation of Sp17 transcripts in primary esophageal squamous cell carcinomas (ESCCs) using differential display and
detected Sp17 transcripts in 86% of ESCCs by RT-PCR, whereas no transcripts were detected in the paired normal esophageal
tissues. Herein we hypothesized that Sp17 might be used as a marker for detecting the response of anticancer therapies in
ESCCs. Our results indicated that Sp17 protein levels in esophageal squamous cancer cell lines decreased in response to
treatment with (i) the HSP90 activity inhibitor geldanamycin, (ii) the tyrosine kinase inhibitor erlotinib and (iii) cisplatin
(chemotherapeutic agent commonly used in management of ESCC). In contrast, the Sp17 levels did not decrease in response
to radiation therapy and treatment with the chemotherapeutic agent, gemcitabine. Further investigations showed that
cisplatin induced decrease in Sp17 levels was due to transcriptional inhibition and cisplatin-resistant cell lines did not show
this decrease in Sp17 levels in response to cisplatin treatment. In addition, we also carried our mass spectophotometric
analysis to identify the binding partners of Sp17 to characterize its possible involvement in esophageal tumorigenesis and
chemoresistance.
Cancer of the esophagus has been reported as the 9th most
common malignancy in the world, with esophageal squamous
cell carcinoma (ESCC) occurring most frequently in develop-
ing countries.1,2 This malignancy is usually detected at an
advanced stage, requiring multimodality treatment. Despite
improvements in its detection, surgical resection and neoad-
juvant therapy, the overall survival of esophageal cancer
patients remains lower than that of patients with many other
solid tumors.3,4 The prognosis of patients who do not
respond to neoadjuvant therapy appears to be poorer than
that of patients who had surgery alone.5,6 Also, ineffective
therapy or excessive therapy to the resistant tumors may
exacerbate the severity of disease. The treatment modalities
such as chemotherapy, which mainly includes cisplatin and
5-fluorouracil alone, or in combination with radiation, have
significantly increased the survival rate of ESCC patients.7
However, recently reported trials using cisplatin-based adju-
vant chemotherapy in resected esophageal cancers, with one
exception, have failed to result in improved survival com-
pared to surgery alone.8–10 These data suggest the need for
predictive markers to allow tailored chemotherapy alone or
in combination with radiation, to increase the number of
complete pathological responses following neoadjuvant
approaches. Recently, molecular markers have been identified
using innovative, molecular-driven technologies to find pre-
dictive and prognostic markers of response to neoadjuvant
and adjuvant therapies in esophageal cancer.
Sperm protein 17 (Sp17) was originally identified as a
novel cancer-testis antigen in various malignancies, including
multiple myeloma.11,12 Recent emerging studies on Sp17 indi-
cated that its expression is not restricted to testis only but is
expressed in other tissues also, albeit at low levels.13 Sp17 is
expressed frequently at the transcript and protein levels in
epithelial ovarian cancers and thus represents a novel ovarian
tumor antigen.14 Overexpression of Sp17 protein has been
observed in gastrointestinal, breast carcinoma, melanoma and
esthesioneuroblastoma.15,16 In an earlier study, we reported
upregulation of Sp17 transcripts in esophageal tumor tissues
using differential display reverse transcription (RT)–polymer-
ase chain reaction (PCR).17 We further detected Sp17 tran-
scripts in 86% of ESCCs by RT-PCR, but no transcripts were
detected in the paired normal esophageal tissues. Importantly,
we showed that the circulating levels of anti-Sp17 antibodies
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were significantly elevated in ESCC patients as compared to
the normal subjects and increasing Sp17 antibody titers were
observed to be associated with progressive disease.18 Recently,
Sp17 was found to be involved in the chemoresistance of
ovarian cancer to paclitaxel.19 However, the status of Sp17
protein levels in chemosensitive and resistant upper-aerodi-
gestive tract cancer cell lines has not been determined. The
pathways in which Sp17 might play an important role remain
to be investigated.
Our study was undertaken to address two questions in
esophageal squamous cancer cell lines: (i) Do Sp17 levels
change in response to chemotherapy and other anticancer
treatments in ESCC? (ii) Does Sp17 hold promise as a molec-
ular marker of response to these treatments in ESCC? We
also carried out the mass spectrometric analysis to investigate
the binding partners of Sp17 in ESCC cell lines in an attempt




The human esophageal squamous cell carcinoma cell line
TE13 and cisplatin-resistant head and neck squamous cell
carcinoma cell lines UMSCC-5Pt and UMSCC10BPt were a
gift from Prof. T. Nishihira (Department of Gastroenterology,
Iwaki Kyoritsu General Hospital, Iwaki, Japan) and Dr.
Thomas E. Carey (University of Michigan, Ann Arbor, MI),
respectively. All these cell lines were cultured in RPMI 1640
medium supplemented with 10% fetal calf serum. All experi-
ments were conducted in serum-containing media. Cells (6 
105) were plated in 100-mm culture dishes 2 days prior to
treatment. For all in vitro experiments, cells were released
from flasks using 0.01% trypsin and 0.2 mmol/l EDTA in
PBS, and cultures were between 30% and 50% confluence at
the time of harvest.
Reagents
Drugs and antibodies: Poly(ADP-ribose) polymerase (PARP)
and actin antibodies were purchased from Cell Signaling
Technology (Beverly, MA). Sp17 antibody was acquired from
Delta Biolabs (Santa Cruz, CA) and phosphorylated Histone
H2AX (c-H2AX) was from Upstate Group LLC (Charlottes-
ville, VA). Erlotinib was kindly provided by Genentech (San
Francisco, CA). Cisplatin and gemcitabine were acquired
from Bedford Laboratories (Bedford, OH) and Eli Lilly,
respectively (Indianapolis, IN). Geldanamycin was purchased
from Sigma (St. Louis, MO). Irradiation of cells was per-
formed using an ortho-voltage machine in the radiation core
facility of the University of Michigan Medical School, MI.
Drugs or radiation treatments
For drug treatments, the most commonly used concentrations
of various drugs in esophageal cancer were used.20–25 It was
also ensured that these concentrations are reported to be
clinically achievable in esophageal cancer patients. Cell lines
were treated with geldanamycin (1 lM), erlotinib (3 lM),
cisplatin (10 lM) and gemcitabine (300 nM) for 2 hr, and
then the old media was replaced with drug-free fresh media.
Plates were harvested at the various time points mentioned
in results. Drugs were diluted in the same media which was
used for growth of the cells and untreated controls were used
to achieve the basal levels which were compared to the treat-
ments at various time points. For radiation, we used 4 Gy,
which is also a clinically achievable dose of ionizing
radiation.
Cisplatin-resistant head and neck cancer cell lines
UMSCC-5Pt and UMSCC10BPt which expressed Sp17 were
treated with cisplatin to determine the effect of drug treat-
ment in these resistant cell lines and compare with cisplatin
treatment response in the sensitive cell line TE-13.
Western blotting
After drug treatments and radiation, at different time points
the cells were harvested and protein samples were prepared
for analysis of proteins by western blotting. Briefly, cells were
scraped using PBS containing sodium orthovanadate and
protease inhibitor mixture (Roche Diagnostic, Indianapolis,
IN). Detergent-soluble proteins were extracted by incubating
cells at 4C for 15 min in extraction buffer [20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 0.1% Triton X-100, 0.1% SDS,
1 mM EDTA, 100 mM NaF, 1 mM Na3Vo4, 1 mM phenyl-
methylsulfonyl fluoride and 1 lg/ml aprotinin]. After particu-
late materials were removed by centrifugation at 13,000 rpm
for 15 min at 4C, protein concentrations in the supernatant
were determined using Bradford reagent (Bio-Rad Laborato-
ries, Hercules, CA). Aliquots containing 40 lg of protein
were diluted with an equal volume of loading buffer [63 mM
Tris-HCl, 2% (w/v) SDS, 10% (v/v) glycerol and 0.005% (w/
v) bromophenol blue], heated to 95C for 5 min and applied
to SDS-polyacrylamide gels. Separated proteins were electro-
phoretically transferred to polyvinylidene fluoride membrane.
Membranes were incubated for 1 hr at room temperature in
blocking buffer consisting of 3% BSA and 1% normal goat
serum in Tris-buffered saline [137 mM NaCl, 20 mM Tris-
HCl (pH 7.6) and 0.1% (v/v) Tween 20] and were subse-
quently incubated overnight at 4C with 1 lg/ml primary
antibody in blocking buffer, washed and again incubated for
1 hr with horseradish peroxidase-conjugated secondary anti-
body (Southern Biotechnology, Birmingham, AL). After three
additional washes in Tris-buffered saline, bound antibody
was detected by enhanced chemiluminescence plus reagent
(Amersham Biosciences, Piscataway, NJ). Some of the mem-
branes were stripped using Restore stripping buffer Pierce
(Rockford, IL) and reprobed with another antibody. For
quantification of relative protein levels, immunoblot films
were scanned and analyzed using ImageJ 1.32j software
(NIH, Bethesda, MD). Unless otherwise indicated, the relative
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Immunocytochemistry
To confirm the changes in Sp17 levels observed by immuno-
blotting, immunocytochemical analysis was performed in
TE13 and UMSCC5Pt and 10BPt. Cells were treated with cis-
platin and proceeded for immunocytochemistry at 24 and 48
hr of treatments and the results were compared to untreated
controls. Immunohistochemical staining was performed by
an immunoperoxidase method using labeled streptavidin–bio-
tin complex (LSAB2 System; DAKO, Carpenteria, CA).
Briefly, TE 13 cells were plated on a glass slide by centrifuga-
tion using Cytospin 4 (Thermoshendon, Pittsburg, PA), air-
dried for 1 hr at room temperature and fixed with cold ace-
tone for 10 min. After a brief washing in PBS, slides were
blocked with 5% normal goat serum for 1 hr and then incu-
bated with rabbit polyclonal anti-human Sp 17 antibody
(dilution, 1:100). After overnight incubation, the slides were
washed (3 PBS) and then incubated with secondary anti-
body at room temperature for 1 hr. 3,3-diaminobenzidine
(DAB) was used as a chromogen and Mayer’s hematoxylin
nuclear stain was used as a counterstain. The stained slides
were mounted with mounting medium Sigma-Aldrich (St.
Louis, MO) and analyzed under an epifluorescence micro-
scope (Labophot-2; Nikon, Melville, NY). Pictures were cap-
tured using a Photometrics Coolsnap CF color camera
(Nikon) and MetaMorph version 4.6.5 software (Universal
Imaging, Downingtown, PA).
Real-time reverse transcription–polymerase chain reaction
To investigate whether the changes in Sp17 levels occur at
RNA levels or protein levels, we performed quantitative real-
time polymerase chain reaction (qRT-PCR) analysis. TE13,
UMSCC5Pt and UMSCC10BPt cell lines were harvested at
various time points after cisplatin treatment, and total RNA
was extracted using an RNeasy Mini Kit (Qiagen, Valencia,
CA) according to the manufacturer’s instruction. qRT-PCR
was performed using the Smart Cycler System (Cepheid, Sun-
nyvale, CA) with Platinum SYBR Green kit (Invitrogen,
Carlsband, CA).Primer sequences used for qRT-PCR for
Sp17, which generated a 102-bp PCR product, are as follows:
forward 50-AAA CAAATAGTCTTCAAAATGAGGAAA-30
and reverse 50-AAG AAGGTTGATGGATTTGGA-30. Opti-
mal annealing temperature was determined and the melt
curve was carefully monitored to ensure PCR results. 2DDCT
method,26 which reflected fold change in expression of the
gene between treated cells and untreated cells, was employed
using GAPDH as the normalized control.
Immunoprecipitation and mass spectrometry
To determine the binding partners of Sp17, the cellular pro-
teins interacting with Sp17 were immunoprecipitated using
anti-Sp17 antibodies and the immunoprecipitates were sub-
jected to liquid chromatography and mass spectrometry anal-
ysis. TE 13 cells were lysed in a minimum volume of immu-
noprecipitation lysis buffer [Tris-HCl buffer (50 mmol/l, pH
8), containing 150 mmol/l NaCl and 1% NP40] and pre-
cleared by incubation with 50 ll of Trublot anti-mouse/anti-
rabbit Ig immunoprecipitation beads for 1 hr at 4C. The
pellet was discarded and the supernatant was subjected to
immunoprecipitation. Cell lysates (500 lg protein) were incu-
bated with 5 lg of specific antibody for 1 hr at 4C. Twenty
microliters of Trublot anti-mouse/anti-rabbit Ig immunopre-
cipitation beads was added and the pellet was further incu-
bated on a rotating device overnight at 4C. The pellet was
then washed 4 times in ice-cold lysis buffer. The supernatant
was discarded and the pellet was resuspended in 50 ll of the
sample buffer. The samples were fractionated by SDS-PAGE.
Several bands were excised and subjected to liquid chroma-
tography/MS/MS analysis in the core Mass Spectrometry Fa-
cility at the University of Michigan Medical School.
MS-MS analysis
To analyze MS-MS results, the data were collected using a
linear ion-trap instrument equipped with nanospray probe
(Thermo Fisher, Waltham, MA). HPLC conditions were 5–
95% buffer B (95% acetonitrile containing 1% acetic acid) for
40 min. Mass spectrometer was operated in a dual play mode
wherein the instrument switched between full MS mode and
MS/MS mode to collect collision-induced dissociation (CID)
data on the 5 most abundant ions. CID data were analyzed
using Bioworks 3.2 (Finnigan, Wayne, MI) by searching
against a human international protein index (IPI) protein
database.
Ingenuity pathway analysis
Ingenuity pathway analysis (IPA) (IngenuityVR Systems, Red-
wood City, CA; www.ingenuity.com) was used to identify the
protein networks in which Sp17 and the proteins coimmuno-
precipitated with Sp17 antibody identified in our study are
involved. Our aim was to determine the biological functions
that are most significant to the genes in the network. Proteo-
mics data were uploaded into IPA Knowledge Base as a tab-
delimited text file of IPI accession numbers. IPA used abbre-
viation names of these proteins to navigate the literature
database. For the detailed information on IPA, visit www.in-
genuity.com. Eligible molecules serve as ‘‘seeds’’ for generat-
ing these networks. Networks are scored based on the num-
ber of network eligible molecules contained in these
networks. The score ¼ log (p-value). The higher the score,
the lower is the probability of finding the observed number





The results are presented as mean 6 SE of at least 3 experi-
ments. Student’s t-test was used to assess the statistical signif-
icance of differences. A significance level threshold of p <
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Results
Cisplatin treatment resulted in rapid and prolonged
degradation of Sp17
We sought to determine the changes in Sp17 levels in
response to various anticancer treatments, namely erlotinib,
geldanamycin, gemcitabine, cisplatin and radiation. The
esophageal cancer cells, TE13, were treated with erlotinib (3
lM), geldanamycin (1 lM), gemcitabine (300 nM) and cis-
platin (10 lM), as per details given in the Methods section
or with radiation (4 Gy) and the protein levels of Sp17,
PARP, cH2AX and GAPDH were determined. Of these treat-
ments, geldanamycin and cisplatin resulted in rapid degrada-
tion of Sp17 protein (within 2 hr); however, the levels
increased further in case of geldanamycin (24 and 48 hr),
whereas cisplatin caused prolonged decrement in Sp17 levels
(48 hr) (Fig. 1a). More than 90% of Sp17 protein degradation
was observed at 48 hr of cisplatin treatment than controls
(Fig. 1b; p < 0.001). Erlotinib also caused reduction in Sp17
levels (2 hr); however, at 48 hr the levels were close to con-
trol levels. Maximum amount of PARP cleavage was observed
in cisplatin-treated cells, showing high sensitivity of these
cells to cisplatin. Radiation treatment did not cause an
increase in cH2AX levels, whereas the levels increased in
response to chemotherapeutic drugs such as gemcitabine and
cisplatin (Fig. 1). An increase in the levels of cH2AX in
response to treatment with anticancer drugs is an indicator
of unrepaired DNA damage. Increased PARP cleavage and
cH2AX levels in response to chemotherapy suggests that
TE13 is a drug-responsive cell line.
In cisplatin-resistant head and neck squamous cell lines,
Sp17 levels did not decrease significantly
Being convinced with the decrease in levels of Sp17 in
response to cisplatin in a sensitive cell line, we next investi-
gated if there is a change in Sp17 levels in response to cispla-
tin in cisplatin-resistant head and neck squamous cell lines,
UMSCC5Pt and UMSCC10BPt cells, which expressed Sp17
(Fig. 2a). Cisplatin treatment in these cisplatin-resistant cell
lines did not cause a significant decrease in Sp17 levels.
Although, the 2 cell lines behaved differently with respect to
Sp17 protein degradation in UMSCC5Pt, at 72 hr, Sp17 levels
were 49% of the controls (p > 0.05), whereas in
UMSCC10BPt the remaining Sp17 protein levels were only
22% (p < 0.05) (Figs. 2b and 2c, respectively). The decrease
in Sp17 levels was not significantly different in UMSCC5Pt
and UMSCC10BPt cells at 24 hr, whereas 90% of Sp17 pro-
tein levels were reduced than control levels in the cisplatin-
sensitive TE13 cell line. Also, there was only a modest
increase in cleaved PARP levels in UMSCC5Pt and almost
Figure 1. (a) Effects of radiation (4 Gy), erlotinib (3 lM),
geldanamycin (1 lM), gemcitabine (300 nM) and cisplatin (10 lM)
on Sp17, PARP, cH2AX and GAPDH levels in TE13 cell line.
Conditions of drug treatments and immunoblotting are described
in the Material and methods section. (b) Bar diagram showing the
changes in Sp17 protein levels in response to cisplatin in the 3
independent immunoblotting experiments.
Figure 2. (a) Effects of cisplatin on Sp17, PARP and GAPDH levels
in relatively cisplatin-resistant UMSCC5Pt and UMSCC10BPt cell
lines. (b, c) Bar diagram showing the changes in Sp17 protein
levels in response to cisplatin in UMSCC5Pt and UMSCC10BPt.
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undetectable PARP cleavage in UMSCC10BPt, suggesting
that these 2 cell lines are comparatively resistant to cisplatin-
induced apoptosis than TE13.
Immunocytochemistry data confirmed lowered expression
of Sp17 after cisplatin treatment in cisplatin-sensitive
cells
Using immunocytochemistry, we further investigated Sp17
levels in response to cisplatin treatment in the cisplatin-
sensitive TE13 and cisplatin-resistant UMSCC5Pt and
UMSCC10BPt cells. After cisplatin treatment, equal numbers
of cells were plated for immunocytochemical analysis. Sp17
expression was found to be significantly decreased in response
to cisplatin compared to the untreated controls in cisplatin-
sensitive TE13 cells, whereas the expression did not decrease
in the cisplatin-resistant UMSCC5Pt and UMSCC10BPt cells
(Fig. 3).
Quantitative real-time PCR analysis confirmed reduction in
Sp17 transcripts on cisplatin treatment in cisplatin-
sensitive cells
To investigate further whether the reduction of Sp17 levels
after cisplatin treatment occurs at the protein or RNA levels,
we carried out qRT-PCR analysis of the Sp17 transcripts. Cis-
platin-sensitive, TE13 and resistant UMSCC5Pt and
UMSCC10BPt cells were plated at a cell density of 2.5  103
cells/well in a 6-well plate and treated with 10 lM cisplatin
for 2, 24, 48 and 72 hr. qRT-PCR analysis revealed a signifi-
cant reduction in expression of Sp17 after 24-hr treatment as
compared to the untreated control cells (Fig. 4a). A differ-
ence of 3 to 4 threshold cycles (Ct) was observed between
control and cisplatin-treated TE13 cells. Decreased Sp17
expression was observed in 48 and 72 hr treated cells (upto
>80%; p < 0.001; Fig. 4b). There was no significant differ-
ence in expression of Sp17 levels in both UMSCC5Pt and
UMSCC10BPt cells after cisplatin treatment (from 2 to 72
hr) as compared to untreated cells (Figs. 4a and 4b). These
data suggest that cisplatin-induced reduction in Sp17 expres-
sion occurs at the transcript level.
Novel binding partners of Sp17 protein
The biological functions of Sp17 in human cancers remain
largely unknown. The above results and our earlier
reports17,18 suggest that it might be involved in tumor growth
and development as well as drug resistance. We speculated
that Sp17 might be important in signaling pathways and it
acts in co-ordinance with many factors. Therefore, we carried
out immunoprecipitation analysis using Sp17 antibody, to
Figure 3. (a–i) Results of immunocytochemistry experiments indicating changes in Sp17 protein levels in response to cisplatin in cisplatin-
sensitive TE13 and relatively cisplatin-resistant UMSCC5Pt and UMSCC10BPt cell lines. [Color figure can be viewed in the online issue,
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Figure 4. (a) Kinetics of Sp17 mRNA in response to cisplatin at various time points in TE13, UMSCC5Pt and UMSCC10Pt cell lines. Sp17
mRNA at various time points 2, 24, 48 and 72 hr after cisplatin treatment were compared to controls. The melting curves depicting Sp17
mRNA start to separate as early as at 2 hr after cisplatin treatment in case of TE13 showing the decrease in levels, whereas the curves did
not separate in case of UMSCC5Pt and UMSCC10BPt showing no change in Sp17 mRNA levels in these cell lines. (b) Bar diagram showing
quantitation of Sp17 mRNA in the 3 cell lines. Results are the indicative of the 3 independent real-time PCR experiments. (c) Network
analysis using ingenuity pathways analysis software. Network analysis classified proteins into 2 networks on the basis of functions
published in the literature; the merged network is shown. Solid lines show direct interactions/regulations, whereas dashed lines show
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identify the binding partner(s) of Sp17. Mass spectrometric
analysis of Sp17 immunoprecipitates resulted in identification
of several proteins that might act as the binding partners of
Sp17 and have known roles in cell survival, cell signaling, tu-
mor growth and metastasis. These proteins are listed in Table
1. The structural organization of Sp17 confirms that some of
these proteins might be binding to Sp17.
Protein network analysis using IPA suggested that 16 net-
work eligible proteins were components of 2 major networks
with scores 26 and 11 comprising 11 and 5 network proteins
identified in our study, respectively (Supporting Information
Table). Figure 4c depicts the merged 2 novel networks to
shed light on the biological significance of the proteins iden-
tified in a cellular context. The complexity of Figure 4c dem-
onstrates the numerous interactions between Sp17 and its pu-
tative interaction partners that are components of
inflammation, stress response, cell signaling, growth and pro-
liferation—cellular processes known to be implicated in
esophageal cancer development. These networks suggest
direct interaction of Sp17 with calmodulin which in turn
shows connections with PI3-Kinase, NFkB, TGFb1, myc,
HIF1A, HSP90AB1 and HSP 70.
Discussion
Molecular markers that can predict the response of various
therapeutic interventions in esophageal cancer patients are
urgently needed. We sought to investigate the changes in lev-
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and chemotherapeutic drugs including erlotinib, geldanamy-
cin, gemcitabine and cisplatin in esophageal squamous carci-
noma cell lines. Our salient findings demonstrated that Sp17
protein levels decreased in response to treatment with (i) the
HSP90 activity inhibitor geldanamycin, (ii) the tyrosine ki-
nase inhibitor erlotinib and (iii) cisplatin (the chemothera-
peutic agent commonly used in management of ESCC). In
contrast, the Sp17 levels did not decrease in response to radi-
ation therapy or treatment with the chemotherapeutic agent
gemcitabine. Further investigations showed that the cisplatin
induced decrease in Sp17 levels was due to transcriptional in-
hibition, and cisplatin-resistant cell lines did not show this
decrease in Sp17 levels in response to cisplatin treatment.
Notably, in the TE13 cell line, of the aforementioned 5
treatments, cisplatin and geldanamycin caused rapid degrada-
tion of Sp17 protein at 6 hr, which correlated with PARP
cleavage at 48 hr. The geldanamycin-induced Sp17 degrada-
tion suggests that Sp17 might be a substrate/client protein for
HSP90 activity, as geldanamycin and other ansamycin deriva-
tives are known to degrade HSP90 substrate proteins.27
Among the HSP90 substrate proteins, Erb2, Src, Akt and
ChK1 are important for cell cycle regulation and the list is
growing.28,29 Whether Sp17 plays a role in DNA damage and
repair is yet to be determined; however, our MS-MS data
showed its interaction with both HSP70 and HSP90, suggest-
ing a possible link.
Importantly, only cisplatin caused almost 90% degradation
of Sp17 protein in TE13 cells at 48 hr. As increased PARP
cleavage and cH2AX levels were also indicative of apoptosis
and unrepaired DNA damage in response to cisplatin at 48
hr, the degradation of Sp17 might be proposed to be a
marker for cisplatin response. Hence, the next step was to
look at Sp17 levels in cisplatin-resistant cell lines. In one of
our earlier reports, we found upregulation of Sp17 mRNA in
oral cancer patients as compared to healthy control sub-
jects.30 Therefore, we used head and neck squamous cell car-
cinoma cell lines, UMSCC5Pt and UMSCC10BPt, as our
model for cisplatin resistance. Cisplatin treatment in these re-
sistant cell lines did not cause a significant decrease in Sp17
levels or affected PARP cleavage, suggesting that Sp17 levels
correlated with cisplatin response and apoptosis, whereas
treatment with other chemotherapeutic agents such as erloti-
nib and geldanamycin as well as radiation did not have such
effects on Sp17 levels, implicating Sp17 in cisplatin resistance.
Importantly, because its downregulation correlated with cis-
platin sensitivity and resultant apoptosis, we propose Sp17 to
be a putative marker for predicting cisplatin response prior
or early in the course of treatment. It is noteworthy that the




Tumor-associated calcium signal transducer 1 precursor TACSTD1 35 Cell–cell adhesion
ERBB3 isoform 1 of receptor tyrosine–protein kinase
erbB-3 precursor
HER3 precursor 180 Receptor tyrosine kinase signaling
Isoform 1 of Bcl-2-associated transcription factor 1 BCLAF1 106 Bcl-2 family member repressor
Hypoxia inducible factor 3, alpha subunit HIF3A 72 Hypoxia sensing, angiogenesis
Annexin A1 ANXA1 38 Membrane fusion, exocytosis
Membrane-associated ring finger MARCH7 78 Ring-finger domain ubiquitin ligase
Tumor protein p53-binding protein, 2 TP53BP2 125 Inhibition of apoptosis
Heat shock 70-kDa protein 9 HSPA9 73 HSP70 family, molecular chaperones
TNF receptor-associated protein/heat shock protein 75 kDa,
mitochondrial precursor
TRAP1 80 Molecular chaperones
Heat shock protein 90 kDa alpha (cytosolic), class B member 1 HSP90AB1 86 HSP90 family, molecular chaperones
Phosphoinositide 3-kinase regulatory subunit 6 PIK3R5 97 PI3K signaling
Phosphoinositide 3-kinase regulatory subunit 2 PIK3R2 85 PI3K signaling
Diacylglycerol kinase, gamma DGKG 89 PI3K signaling
Vav 2 oncogene VAV 2 60 Receptor tyrosine kinase signaling
Proto-oncogene tyrosine–protein kinase Yes YES1 60 Receptor tyrosine kinase signaling
Guanine nucleotide exchange factor p532 HERC1 72 Ras signaling; GTP-binding proteins
Ras-related protein-19 RAB19 49 Ras signaling; GTP-binding proteins
A kinase anchor protein 8 AKAP8 95 Protein kinase A signaling
Calcium-binding protein 39 CAB39 39 Calcium signaling
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risk factors for esophageal cancer development might vary
across different ethnic groups, and therefore, it is possible that
the response to a particular type of treatment may be different
because of distinct signaling pathways. Notably, a recent report
demonstrating the involvement of Sp17 in chemoresistance in
human epithelial ovarian cancer is in agreement with our find-
ings.19 However, these authors did not determine the pheno-
type in sensitive cisplatin cell lines and the influence on Sp17
protein levels was also not reported. Our results also indicated
that the reduction in Sp17 protein levels is due to the downreg-
ulation of Sp17 transcripts in response to cisplatin. At present,
we do not know what is/are the transcriptional repressor(s) of
Sp17 in response to cisplatin; nevertheless, several reports
observed the differential gene expression profiles of cisplatin-
sensitive and resistant tumors.31–33
The biological role of Sp17 in the development of esopha-
geal cancer is yet unknown. Immunoprecipitation and mass
spectrometry data combined with IPA showed the interaction
of Sp17 with the calcium-binding protein calmodulin and
cAMP-dependent protein kinase, which are expected from its
structural organization. The N-terminal domain of Sp17 is
almost totally conserved among all species studied and has a
high homology to the cAMP-dependent protein kinase A reg-
ulatory subunit II, which is essential for protein dimerization
and interaction with protein kinase A-anchoring proteins.34
Sp17 protein has a central sulphated carbohydrate-binding
domain and its C-terminal contains an ‘‘IQ’’ motif which is a
Ca2þ/calmodulin-binding domain.35 Expectedly, the binding
partners of Sp17 include A kinase anchor protein 8 and cal-
cium-binding protein 39. In addition, the central portion of
Sp17 contains a region that binds carbohydrates and is impli-
cated in cell–cell adhesion,36 which might help in cell adhe-
sion and angiogenesis during tumorigenesis.
The goal of this pathway analysis approach was to estab-
lish a hypothesis to unravel new protein connections between
Sp17 and components of cellular pathways. In this context,
IPA of the identified novel binding partners of Sp17 revealed
their involvement in cell proliferation, cell–cell adhesion,
angiogenesis, molecular chaperones, PI3K signaling and re-
ceptor tyrosine kinase signaling. It also revealed some major
hubs in these networks where multiple connections arrive or
irradiate to the rest of the network—Sp17 direct interaction
with calmodulin which is connected to other major hubs that
include PI3-kinase, NFjB, TGFb1, myc, HIF1A, HSP90AB1
and HSP70, suggesting that Sp17 may be found to be indi-
rectly implicated in cell proliferation, stress response and cell
signaling. Functional testing is however warranted for the
validation of Sp17 interactions with the individual proteins
deduced from this approach. In this context it is noteworthy
that 2 of the proteins identified in these networks, namely A-
kinase anchoring protein (AKAP) and ropporin or rhophilin-
associated protein 1, have been reported to be associated
with Sp17. Lea et al.,37 demonstrated the association of Sp17
with A-kinase anchoring protein 3 (AKAP3) in flagella. In
another report, a yeast 2-hybrid system using Sp17 identified
ropporin as a novel cancer-testis antigen in hematologic
malignancies.38 Further, both ropporin and AKAP-associated
sperm protein have been shown to bind AKAP3.39 Ropporin
binds rhophilin, a GTPase Rho-binding protein, involved in
the Rho signal transduction pathway.40 In this way, AKAP3
acts as a scaffold protein for 2 independent signal transduc-
tion pathways. These studies support our network-based
approach for unraveling novel interaction partners and func-
tions of Sp17 in esophageal tumorigenesis.
Collectively, our data strongly suggest Sp17 to be a novel
marker for predicting cisplatin response in ESCC. Further
studies in this direction should focus on its involvement in
various signaling pathways involved in DNA damage and
repair.
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